<DOC>
	<DOC>NCT02603952</DOC>
	<brief_summary>The purpose of this study is to evaluate safety and tolerability of a single dose of MEDI8852 when given with oseltamivir, the safety and tolerability of oseltamivir alone, and the safety and tolerability of a single dose of MEDI8852 alone in adult subjects with acute, uncomplicated influenza caused by Type A strains.</brief_summary>
	<brief_title>A Phase 2a to Evaluate the Safety of MEDI8852 in Adults With Uncomplicated Influenza</brief_title>
	<detailed_description>The MEDI8852 phase 2a study will evaluate the safety and tolerability of a single intravenous (IV) dose of MEDI8852 administered in conjunction with oseltamivir, the safety and tolerability of oseltamivir alone and the safety and tolerability of a single IV dose of MEDI8852 alone in adult subjects with confirmed acute, uncomplicated influenza caused by Type A strains. Enrollment is planned at approximately 50 sites in the United States, South Africa, and Australia.</detailed_description>
	<mesh_term>Influenza, Human</mesh_term>
	<mesh_term>Oseltamivir</mesh_term>
	<criteria>Age 18 through 65 years at the time of screening. Symptomatic presumptive Influenza A infection with onset of symptoms ≤ 5 days prior to MEDI8852 administration and defined as the presence of: Fever of ≥ 38.0ºC (100.4°F) at screening AND ≥ 1 moderate systemic symptom (headache, malaise, myalgia, sweats and/or chills, or fatigue) AND 1 moderate respiratory symptom (cough, sore throat, or nasal symptoms) Influenza A infection confirmed with positive rapid antigen test Able to complete the followup period through Day 101 as required by protocol (including telephone followup for Days 11 to 101) Females of childbearing potential who are sexually active with a nonsterilized male partner must use a highly effective method of contraception for at least 2 days prior to the first dose of investigational product and must agree to continue using such precautions through Day 101 of the study Hospitalized subjects. Receipt of influenza antiviral therapy within the preceding 14 days. Receipt of immunoglobulin or blood products within 6 months prior to screening. Known immunodeficiency due to illness, including HIV, or due to drugs, including any course of glucocorticoid therapy exceeding 2 weeks of prednisone or equivalent at a dose of 20 mg daily or every other day within 6 months prior to screening. Current clinical evidence of pneumonia. Active bacterial infection requiring treatment with oral or parenteral antibiotics. History of malignancy other than treated nonmelanoma skin cancers or locallytreated cervical cancer in previous 3 years. Any planned surgical procedure before completion of Day 101.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>December 2016</verification_date>
	<keyword>Influenza</keyword>
	<keyword>Influenza A</keyword>
	<keyword>Flu</keyword>
	<keyword>Flu A</keyword>
</DOC>